裴氏“兰州方”治疗慢性粒细胞白血病的临床观察及疗效研究-peishis.docxVIP

中文摘要目的：本研究通过对裴正学教授的“兰州方”加西药化疗对慢性粒细胞性白血病患者的临床观察以及疗效分析，并与单纯西药化疗组进行了对比。根据患者外周血象、骨髓象及临床症状体征的变化，来探讨裴氏“兰州方”提高骨髓的正常造血功能，改善患者临床症状的效果及机制。为其在临床中的广泛应用提供充分的科学理论依据。方法：30例患者随机分组，分为对照组（单纯西药化疗）和治疗组（“兰州方”加西药化疗）。两组患者在入组时年龄、性别、临床症状体征、血象、骨髓增生程度等一般性资料方面经X2检验，(P0.05)均无显著性差异，治疗3个月后，临床观察患者血象、骨髓象以及临床症状体征，并对两组患者进行比较疗效分析。结果：(1)经t检验(p0.05)，治疗组消失时间较对照组明显缩短。消失率经X2检验(p0.05)，表明治疗组消失率较对照组也显著提高。(2)治疗前后治疗组与对照组Hb、WBC、PLT变化无显著性差异(p0.05)。(3)治疗前后治疗组较对照组骨髓恶性增生程度降低，两组比较有统计学意义（P＜0.05）。结论：通过本次临床研究，表明中西医结合治疗在改善慢粒患者的症状，提高骨髓的正常造血功能方面较单纯西药化疗更具优势，表明裴氏“兰州方”可以增强骨髓正常造血功能，并且对于西医化疗治疗慢粒有协同增效作用，为本方药日后在临床推广应用提供了依据。关键词：裴正学；兰州方；慢性粒细胞白血病ABSTRACTObjective:ToanalyzeeffectthatLanzhouprescriptionandchemotherapydrugswhichtreatchronicmyeloidleukemiabyclinicalobservation,andcomparewiththegroupofchemotherapydrugs.Patientswithperipheralblood,bonemarrow,andchangesinclinicalsymptomsandsigns,toexplorePeiLanzhousidetoimprovebonemarrowhematopoieticfunction,andimprovetheeffectandmechanismoftheclinicalsymptoms.ItsfullscientifictheoreticalbasisforthewidelyusedinclinicalMethods:Thirtypatientswererandomlygroupedintocontrolgroup(onlywesternchemotherapy)andtreatmentgroup(Lanzhousidewesternmedicinechemotherapy).Patientswereenrolled,age,gender,diseaseduration,andothergeneralinformation,therewasnosignificantdifferencebetweenthe3monthsoftreatment,clinicalobservationsofpatientswithblood,bonemarrow,aswellasclinicalsymptomsandsigns,andtwogroupsofpatientstocomparetheefficacyanalysis.Results:(1)Byt-test(p0.05),thedisappearancetimeofthetreatmentgroupcomparedwiththecontrolgroupwassignificantlyshortened.TherateofdisappearanceoftheX2test(p0.05),indicatingthattreatmentgroupdisappearanceratethanthecontrolgroupalsoimprovedsignificantly.Beforeandaftertreatment,thetreatmentgroupandcontrolgroup,Hb,WBC,thePLTchangewasnosignificantdifference(p0.05).Beforeandaftertreatmentthetreatmentgroupcomparedwiththecontrolofmalignantbonemarrowhyperplasiareducethetwogroupswasstatisticallysignificant(P0.05).Conclusion:Thisclinicalstudy,thatthewesterndrugchemotherapymoreadvantageo